Register for our S/EIS Fund

Orfan Biotech, a company dedicated to developing small molecules for the treatment of Primary Hyperoxaluria

o2h discovery Update: Orfan Biotech, a company dedicated to developing small molecules for the treatment of Primary Hyperoxaluria. Orfan has a collaboration with o2h discovery involving financial and medicinal chemistry support. Hans Maag, Med Chemist, Orfan, “We are very thankful to the research partnership with o2h discovery which is allowing Orfan to efficiently and effectively drive our Medicinal Chemistry programs. This partnership demonstrates the power of bringing together insights generated by the Orfan founders with state-of-the art drug discovery and chemistry expertise built in collaboration with the o2h discovery”

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative

o2h discovery are working with new Boston based start-up Arrakis, supporting discovery efforts and making the seed funding stretch further

o2h discovery are working with new Boston based start-up Arrakis, supporting discovery efforts and making the seed funding stretch further! “Happy to be working with o2h discovery, now that I’m sailing under a new flag. Thanks to the energy and effort of the team at o2h discovery, Arrakis Therapeutics is moving very rapidly to build an exciting new technology. Many thanks to all !” Dr Russ Petter, USA.

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative